Decrease in sigma but no increase in striatal dopamine D4 sites in schizophrenic brains.
[3H]Nemonapride differentially defines sigma and dopamine receptor sites depending upon assay conditions. In post-mortem schizophrenic brain tissues, [3H]nemonapride-labeled sigma receptor binding is decreased compared to match normal controls. No striatal dopamine D4/D4-like receptor differential was observed between the schizophrenic or control tissues, using the [3H]nemonapride minus [3H]raclopride subtraction method.
Helmeste
D M
DM
Department of Psychiatry, University of California at Irvine, 92697, USA.
Tang
S W
SW
Bunney
W E
WE
Potkin
S G
SG
Jones
E G
EG
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D003342:Corpus Striatum / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017448:Receptors, Dopamine D2 / Q000378:metabolism*; D050638:Receptors, Dopamine D4; D017480:Receptors, sigma / Q000378:metabolism*; D012559:Schizophrenia / Q000378:metabolism*
C493599:DRD4 protein, human; D017448:Receptors, Dopamine D2; D017480:Receptors, sigma; D050638:Receptors, Dopamine D4